In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...
16don MSN
Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...
Verywell Health on MSN
Understanding metastatic castration-resistant prostate cancer
Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...
Scott Adams Dies of Cancer at 69: What Is Metastatic Prostate Cancer - Signs One Should Never Ignore
Scott Adams, the creator of the widely acclaimed comic strip Dilbert, has died at the age of 68, according to an announcement ...
Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...
University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...
(CNN) — President Joe Biden’s diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his prognosis?
When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic ...
Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results